{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Low+Breast+Carcinoma&page=3", "query": { "condition": "HER2 Low Breast Carcinoma", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 70, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Low+Breast+Carcinoma&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Low+Breast+Carcinoma&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T23:45:59.959Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04556773", "title": "A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2020-12-17", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-10-08T23:45:59.959Z", "location_count": 9, "location_summary": "Commack, New York • Harrison, New York • New York, New York + 5 more", "locations": [ { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Uniondale", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04556773" }, { "nct_id": "NCT07198724", "title": "ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "HER2 Low Breast Carcinoma", "HER2-negative Breast Cancer", "Breast Cancer", "Breast Cancer Female" ], "interventions": [ { "name": "Elacestrant", "type": "DRUG" }, { "name": "Trastuzumab Deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kristina A. Fanucci", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2025-11-17", "completion_date": "2038-06-01", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-08T23:45:59.959Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07198724" }, { "nct_id": "NCT07729046", "title": "Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Invasive Breast Cancer", "Resistant Breast Cancer", "ER+, HER2-, Metastatic Breast Cancer" ], "interventions": [ { "name": "Neratinib + endocrine therapy", "type": "DRUG" }, { "name": "Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant", "type": "DRUG" }, { "name": "CDK4/6 + Endocrine therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 150, "start_date": "2027-07", "completion_date": "2035-06", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-08T23:45:59.959Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07729046" }, { "nct_id": "NCT04553770", "title": "Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Early-stage Breast Cancer", "Hormone Receptor Positive Breast Carcinoma", "Invasive Breast Cancer", "Stage II Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage III Breast Cancer" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2020-10-09", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-10-08T23:45:59.959Z", "location_count": 9, "location_summary": "Fullerton, California • Los Alamitos, California • Los Angeles, California + 6 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04553770" }, { "nct_id": "NCT04443348", "title": "Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer", "Hormone Receptor Positive (HR+), HER2-negative Breast Cancer", "Biopsy-proven, Positive Lymph Node(s)" ], "interventions": [ { "name": "Radiation Therapy Boost", "type": "RADIATION" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Laura M. Spring, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2020-12-16", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-08T23:45:59.959Z", "location_count": 10, "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 6 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04443348" }, { "nct_id": "NCT03238703", "title": "Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HER2/Neu Negative", "Invasive Breast Carcinoma", "Postmenopausal", "Stage 0 Breast Cancer", "Stage IA Breast Cancer" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Tamoxifen Citrate", "type": "DRUG" }, { "name": "Toremifene Citrate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "FEMALE", "summary": "60 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2018-09-01", "completion_date": "2025-03-14", "has_results": false, "last_update_posted_date": "2018-12-27", "last_synced_at": "2026-10-08T23:45:59.959Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03238703" }, { "nct_id": "NCT05705401", "title": "Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2-positive Breast Cancer" ], "interventions": [ { "name": "Standard of Care Adjuvant Breast Radiation", "type": "RADIATION" }, { "name": "Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 1300, "start_date": "2023-05-19", "completion_date": "2037-02-01", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-10-08T23:45:59.959Z", "location_count": 413, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 286 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Antioch", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05705401" }, { "nct_id": "NCT07287917", "title": "Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma (Skin Cancer)", "HER2-low Hormone Receptor Positive Breast Cancer" ], "interventions": [ { "name": "AMXT 1501 Dicaprate", "type": "DRUG" }, { "name": "DFMO", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aminex Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2026-01-26", "completion_date": "2028-12-29", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-08T23:45:59.959Z", "location_count": 20, "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07287917" }, { "nct_id": "NCT00726180", "title": "Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "trastuzumab (Herceptin®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1, "start_date": "2008-07", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2013-10-15", "last_synced_at": "2026-10-08T23:45:59.959Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00726180" }, { "nct_id": "NCT06533826", "title": "TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "HER2-low Breast Cancer", "Metastatic Breast Cancer", "HER2-negative Breast Cancer" ], "interventions": [ { "name": "Trastuzumab Deruxtecan", "type": "DRUG" }, { "name": "Datopotamab Deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ana C Garrido-Castro, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 357, "start_date": "2024-10-29", "completion_date": "2038-08-01", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-08T23:45:59.959Z", "location_count": 11, "location_summary": "Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06533826" } ] }